- Home
- IKNA vs ARMP Comparison
IKNA vs ARMP Comparison
Compare IKNA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- ARMP
- Stock Information
- Founded
- IKNA 2016
- ARMP 2016
- Country
- IKNA United States
- ARMP United States
- Employees
- IKNA N/A
- ARMP N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IKNA Health Care
- ARMP Health Care
- Exchange
- IKNA Nasdaq
- ARMP Nasdaq
- Market Cap
- IKNA 64.7M
- ARMP 73.8M
- IPO Year
- IKNA 2021
- ARMP N/A
- Fundamental
- Price
- IKNA $1.32
- ARMP $1.58
- Analyst Decision
- IKNA Buy
- ARMP Strong Buy
- Analyst Count
- IKNA 2
- ARMP 1
- Target Price
- IKNA $3.00
- ARMP $7.00
- AVG Volume (30 Days)
- IKNA 84.4K
- ARMP 14.4K
- Earning Date
- IKNA 03-06-2025
- ARMP 03-20-2025
- Dividend Yield
- IKNA N/A
- ARMP N/A
- EPS Growth
- IKNA N/A
- ARMP N/A
- EPS
- IKNA N/A
- ARMP N/A
- Revenue
- IKNA N/A
- ARMP $5,174,000.00
- Revenue This Year
- IKNA N/A
- ARMP $8.43
- Revenue Next Year
- IKNA N/A
- ARMP N/A
- P/E Ratio
- IKNA N/A
- ARMP N/A
- Revenue Growth
- IKNA N/A
- ARMP 14.24
- 52 Week Low
- IKNA $1.22
- ARMP $1.58
- 52 Week High
- IKNA $1.94
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- IKNA 43.56
- ARMP 30.25
- Support Level
- IKNA $1.27
- ARMP $1.63
- Resistance Level
- IKNA $1.43
- ARMP $2.30
- Average True Range (ATR)
- IKNA 0.07
- ARMP 0.15
- MACD
- IKNA 0.00
- ARMP -0.04
- Stochastic Oscillator
- IKNA 37.21
- ARMP 0.00
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.